Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy

A. Casadei Gardini, A. Passardi, L. Fornaro, P. Rosetti, M. Valgiusti, S. Ruscelli, M. Monti, C. Casadei, F. Pagan, G. L. Frassineti

Research output: Contribution to journalReview article

Abstract

The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy.

Original languageEnglish
Pages (from-to)52-56
Number of pages5
JournalCritical Reviews in Oncology/Hematology
Volume123
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Anal Canal
Epidermal Growth Factor Receptor
Immunotherapy
Squamous Cell Carcinoma
Therapeutics
Radiotherapy
Incidence
Research
Neoplasms

Keywords

  • Anal cancer
  • Anti-EGFR
  • Cetuximab
  • Immunotherapy
  • Nivolumab
  • Panitumumab
  • Pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{ef803e31e3af499ebc8a776259a674f0,
title = "Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy",
abstract = "The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy.",
keywords = "Anal cancer, Anti-EGFR, Cetuximab, Immunotherapy, Nivolumab, Panitumumab, Pembrolizumab",
author = "{Casadei Gardini}, A. and A. Passardi and L. Fornaro and P. Rosetti and M. Valgiusti and S. Ruscelli and M. Monti and C. Casadei and F. Pagan and Frassineti, {G. L.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.critrevonc.2018.01.007",
language = "English",
volume = "123",
pages = "52--56",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Treatment of squamous cell carcinoma of the anal canal

T2 - A new strategies with anti-EGFR therapy and immunotherapy

AU - Casadei Gardini, A.

AU - Passardi, A.

AU - Fornaro, L.

AU - Rosetti, P.

AU - Valgiusti, M.

AU - Ruscelli, S.

AU - Monti, M.

AU - Casadei, C.

AU - Pagan, F.

AU - Frassineti, G. L.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy.

AB - The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy.

KW - Anal cancer

KW - Anti-EGFR

KW - Cetuximab

KW - Immunotherapy

KW - Nivolumab

KW - Panitumumab

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85044863828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044863828&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2018.01.007

DO - 10.1016/j.critrevonc.2018.01.007

M3 - Review article

C2 - 29482779

AN - SCOPUS:85044863828

VL - 123

SP - 52

EP - 56

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -